Common use of Publication Rights Clause in Contracts

Publication Rights. Each Party shall submit to the other Party for review and approval all proposed academic, scientific and medical publications and public presentations relating to any activities under this Agreement for review in connection with preservation of Patent Rights and trade secrets or to determine whether Confidential Information should be modified or deleted from the proposed publication or public presentation. Written copies of such proposed publications and presentations shall be submitted to the non-publishing or non-presenting Party no later than […***…] days before the planned submission for publication or presentation and the non-publishing or non-presenting Party shall provide its comments with respect to such publications and presentations within […***…] days after its receipt of such written copy. The review period may be extended for an additional […***…] days if the non-publishing or non-presenting Party can demonstrate a reasonable need for such extension including, without limitation, the preparation and filing of patent applications (which extension shall not be unreasonably withheld or delayed). By written agreement, this period may be further extended (which extension shall not be unreasonably withheld or delayed). Without limiting the foregoing, no publication or presentation shall be made unless and until the non-publishing or non-presenting Party ‘s reasonable comments on the proposed publication or presentation have been addressed and any information has been removed that is determined by the non-publishing or non-presenting Party to be its Confidential Information or that the non-publishing or non-presenting Party desires to maintain in secrecy to preserve the value of its rights under this Agreement. The Parties will each comply with standard academic practice regarding authorship of scientific publications or presentations and recognition of contribution of other Persons in any publications or presentations relating to a Licensed Product and/or Selected Compound or any discovery, research or Development activities under this Agreement.

Appears in 2 contracts

Samples: Research Collaboration and License Agreement (Mirati Therapeutics, Inc.), Research Collaboration and License Agreement (Mirati Therapeutics, Inc.)

AutoNDA by SimpleDocs

Publication Rights. Each During the Term, the following restrictions shall apply with respect to possible disclosure by any Party of any other Party’s Confidential Information relating to Licensed Products in any publication or presentation. A Party (the “Publishing Party”) shall submit to provide the other Party with a copy of any proposed publication or presentation at least 30 days before submission for review and approval all proposed academic, scientific and medical publications and public presentations relating publication by the Publishing Party or its Affiliates so as to provide such other Party with an opportunity to recommend any activities under this Agreement for review in connection with preservation of Patent Rights and trade secrets or changes it reasonably believes are necessary to determine whether continue to maintain the Confidential Information should disclosed by the other Party to the Publishing Party in accordance with the requirements of this Agreement. The incorporation of such recommended changes shall not be modified or deleted from unreasonably refused; and if such other Party notifies (“Notice”) the Publishing Party in writing, within 30 days after receipt of the copy of the proposed publication or public presentation, that such publication or presentation in its reasonable judgment (a) contains an invention, solely or jointly conceived or reduced to practice by the other Party, for which the other Party reasonably desires to obtain patent protection or (b) could be expected to have a material adverse effect on the commercial value of any Confidential Information disclosed by the other Party to the Publishing Party, the Publishing Party shall prevent such publication or delay such publication for a mutually agreeable period of time. Written copies In the case of such proposed publications and presentations inventions, a delay shall be submitted for a period reasonably sufficient to permit the timely preparation and filing of a patent application(s) on such invention, and in no event less than 90 days after the date of the Notice. In the case of Confidential Information, any of the non-publishing or non-presenting Party no later than […***…] days before the planned submission for publication or presentation and the non-publishing or non-presenting Party Party’s Confidential Information shall provide its comments with respect to such publications and presentations within […***…] days after its receipt of such written copybe deleted as requested. The review period may be extended for an additional […***…] days if Parties hereby agree that the non-publishing or non-presenting Party can demonstrate a reasonable need for such extension includingpublication review may diminish over time and agree, without limitationevery six months, to discuss and attempt to agree upon whether and/or when the preparation and filing of patent applications (which extension shall not be unreasonably withheld or delayed). By written agreement, obligations under this period Section 8.6 may be further extended (which extension shall not be unreasonably withheld or delayed). Without limiting the foregoing, no publication or presentation shall be made unless and until the non-publishing or non-presenting Party ‘s reasonable comments on the proposed publication or presentation have been addressed and any information has been removed that is determined by the non-publishing or non-presenting Party to be its Confidential Information or that the non-publishing or non-presenting Party desires to maintain in secrecy to preserve the value of its rights under this Agreement. The Parties will each comply with standard academic practice regarding authorship of scientific publications or presentations and recognition of contribution of other Persons in any publications or presentations relating to a Licensed Product and/or Selected Compound or any discovery, research or Development activities under this Agreementdiscontinued.

Appears in 2 contracts

Samples: License Agreement (Apricus Biosciences, Inc.), License Agreement (Apricus Biosciences, Inc.)

Publication Rights. Each Until the first anniversary of the Effective Date, the following restrictions shall apply with respect to possible disclosure by either Party of the other Party’s Confidential Information relating to Licensed Products in any publication or presentation. A Party (the “Publishing Party”) shall submit to provide the other Party with a copy of any proposed publication or presentation at least 30 days before submission for review and approval all proposed academic, scientific and medical publications and public presentations relating publication by the Publishing Party or its Affiliates so as to provide such other Party with an opportunity to recommend any activities under this Agreement for review in connection with preservation of Patent Rights and trade secrets or changes it reasonably believes are necessary to determine whether continue to maintain the Confidential Information should disclosed by the other Party to the Publishing Party in accordance with the requirements of this Agreement. The incorporation of such recommended changes shall not be modified or deleted from unreasonably refused; and if such other Party notifies (“Notice”) the Publishing Party in writing, within 30 days after receipt of the copy of the proposed publication or public presentation, that such publication or presentation in its reasonable judgment (a) contains an invention, solely or jointly conceived or reduced to practice by the other Party, for which the other Party reasonably desires to obtain patent protection or (b) could be expected to have a material adverse effect on the commercial value of any Confidential Information disclosed by the other Party to the Publishing Party, the Publishing Party shall prevent such publication or delay such publication for a mutually agreeable period of time. Written copies In the case of such proposed publications and presentations inventions, a delay shall be submitted for a period reasonably sufficient to permit the timely preparation and filing of a patent application(s) on such invention, and in no event less than 90 days after the date of the Notice. In the case of Confidential Information, any of the non-publishing or non-presenting Party no later than […***…] days before the planned submission for publication or presentation and the non-publishing or non-presenting Party Party’s Confidential Information shall provide its comments with respect to such publications and presentations within […***…] days after its receipt of such written copybe deleted as requested. The review period may be extended for an additional […***…] days if Parties hereby agree that the non-publishing or non-presenting Party can demonstrate a reasonable need for such extension includingpublication review may diminish over time and agree, without limitationevery six months, to discuss and attempt to agree upon whether and/or when the preparation and filing of patent applications (which extension shall not be unreasonably withheld or delayed). By written agreement, obligations under this period Section 7.6 may be further extended (which extension shall not be unreasonably withheld or delayed). Without limiting the foregoing, no publication or presentation shall be made unless and until the non-publishing or non-presenting Party ‘s reasonable comments on the proposed publication or presentation have been addressed and any information has been removed that is determined by the non-publishing or non-presenting Party to be its Confidential Information or that the non-publishing or non-presenting Party desires to maintain in secrecy to preserve the value of its rights under this Agreement. The Parties will each comply with standard academic practice regarding authorship of scientific publications or presentations and recognition of contribution of other Persons in any publications or presentations relating to a Licensed Product and/or Selected Compound or any discovery, research or Development activities under this Agreementdiscontinued.

Appears in 2 contracts

Samples: License Agreement (Ligand Pharmaceuticals Inc), License Agreement (Tg Therapeutics, Inc.)

AutoNDA by SimpleDocs

Publication Rights. Each During the Term, the following restrictions shall apply with respect to possible disclosure by either Party of the other Party’s Confidential Information relating to Licensed Product in any publication or presentation. A Party (the “Publishing Party”) shall submit to provide the other Party with a copy of any proposed publication or presentation at least [***] days before submission for review and approval all proposed academic, scientific and medical publications and public presentations relating publication by the Publishing Party or its Affiliates so as to provide such other Party with an opportunity to recommend any activities under this Agreement for review in connection with preservation of Patent Rights and trade secrets or changes it reasonably believes are necessary to determine whether continue to maintain the Confidential Information should disclosed by the other Party to the Publishing Party in accordance with the requirements of this Agreement. The incorporation of such recommended changes shall not be modified or deleted from unreasonably refused; and if such other Party notifies (“Notice”) the Publishing Party in writing, within [***] days after receipt of the copy of the proposed publication or public presentation, that such publication or presentation in its reasonable judgment (a) contains an invention, solely or jointly conceived or reduced to practice by the other Party, for which the other Party reasonably desires to obtain patent protection or (b) could be expected to have a material adverse effect on the commercial value of any Confidential Information disclosed by the other Party to the Publishing Party, the Publishing Party shall prevent such publication or delay such publication for a mutually agreeable period of time. Written copies In the case of such proposed publications and presentations inventions, a delay shall be submitted for a period reasonably sufficient to permit the timely preparation and filing of a patent application(s) on such invention, and in no event less than [***] days after the date of the Notice. In the case of Confidential Information, any of the non-publishing or non-presenting Party no later than Party’s Confidential Information shall be deleted as requested. [***…] days before the planned submission for publication or presentation and the non-publishing or non-presenting Party shall provide its comments with respect to such publications and presentations within […***…] days after its receipt of such written copy. The review period may be extended for an additional […***…] days if the non-publishing or non-presenting Party can demonstrate a reasonable need for such extension including, without limitation, the preparation and filing of patent applications (which extension shall not be unreasonably withheld or delayed). By written agreement, this period may be further extended (which extension shall not be unreasonably withheld or delayed). Without limiting the foregoing, no publication or presentation shall be made unless and until the non-publishing or non-presenting Party ‘s reasonable comments on the proposed publication or presentation have been addressed and any information has been removed that is determined by the non-publishing or non-presenting Party to be its Confidential Information or that the non-publishing or non-presenting Party desires to maintain in secrecy to preserve the value of its rights under this Agreement. The Parties will each comply with standard academic practice regarding authorship of scientific publications or presentations and recognition of contribution of other Persons in any publications or presentations relating to a Licensed Product and/or Selected Compound or any discovery, research or Development activities under this Agreement].

Appears in 1 contract

Samples: Research and License Agreement (Ligand Pharmaceuticals Inc)

Time is Money Join Law Insider Premium to draft better contracts faster.